2. Cytoskeleton Metabolic Enzyme/Protease
  3. Integrin MMP
  4. KAFDITYVRLKF

KAFDITYVRLKF 是一种选择性的、竞争性的整合素 αvβ3 结合剂。KAFDITYVRLKF 可诱导 MMP-9 产生。KAFDITYVRLKF 可阻断单核细胞迁移、促进黑色素瘤细胞的迁移、保护神经元、改善运动与认知功能。KAFDITYVRLKF 可用于黑色素瘤、帕金森病的相关研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

KAFDITYVRLKF

KAFDITYVRLKF Chemical Structure

CAS No. : 208116-26-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

KAFDITYVRLKF 相关抗体

Top Publications Citing Use of Products

查看 Integrin 亚型特异性产品:

查看所有亚型
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

查看 MMP 亚型特异性产品:

查看所有亚型
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

KAFDITYVRLKF is a selective, competitive integrin αvβ3 binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease[1][2].

IC50 & Target[1]

MMP-9

 

αvβ3

 

体外研究
(In Vitro)

KAFDITYVRLKF (100 μg/mL; 5 h) 在 Boyden 小室实验中可强烈促进 B16-F10 小鼠黑色素瘤细胞的迁移[1]。
KAFDITYVRLKF (2-20 μg/mL; 16 h) 可呈剂量依赖性促进 B16-F10 小鼠黑色素瘤细胞分泌 MMP-9，在 20 μg/mL 作用 16 h 后分泌量约提升 8 倍，但对 MMP-2 的生成无影响[1]。
KAFDITYVRLKF 可选择性结合 αvβ3 并减少单核细胞穿过内皮细胞的迁移[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

KAFDITYVRLKF 相关抗体:

Cell Migration Assay [1]

Cell Line: B16-F10 mouse melanoma cells
Concentration: 100 μg/mL
Incubation Time: 5 h
Result: Stimulated migration of B16-F10 cells, with the strongest enhancement activity among tested peptides.
Showed activity comparable to that of peptide A-13.
体内研究
(In Vivo)

KAFDITYVRLK (0.2 mg；静脉注射；单次给药) 可显著增强雌性 C57BL6/N 小鼠体内 B16-F10 黑色素瘤细胞的实验性肺转移，使平均肺集落数增加至 481，较对照组水平提升 3 倍[1]。
KAFDITYVRLKF (2 mg/100 g；静脉注射；每日 1 次；连续 14 天) 可保护多巴胺能和 γ-氨基丁酸能神经元，减轻神经炎症和血脑屏障破坏，并改善 MPTP (HY-W114750) 诱导的帕金森病小鼠的运动及认知功能[2]。
KAFDITYVRLKF (2 mg/100 g；静脉注射；每日 1 次；连续 14 天) 可保护多巴胺能和 γ-氨基丁酸能神经元，减轻神经炎症和血脑屏障破坏，并改善 6-OHDA (HY-B1081) 诱导的帕金森病大鼠的运动及认知功能[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 200-250 g, 6-OHDA-induced dopaminergic neuron degeneration)[2]
Dosage: 2 mg/100 g
Administration: i.v.; once daily; 14 consecutive days
Result: Ameliorated locomotor impairment in the open field test (increased total traveled distance and mean velocity relative to vehicle-treated 6-OHDA rats).
Improved motor coordination in the rotarod test (increased time spent on the rotating device relative to vehicle-treated 6-OHDA rats).
Rescued spatial cognitive impairment in the novel object recognition test (increased discrimination score relative to vehicle-treated 6-OHDA rats).
Reduced synchronous contraction of agonist and antagonist hindlimb muscles relative to vehicle-treated 6-OHDA rats.
Reduced serum IL-6 and ROS levels relative to vehicle-treated 6-OHDA rats.
Reduced CNS inflammatory cell infiltration.
Suppressed microglial activation (reduced Iba-1+ cell count in striatum and substantia nigra relative to vehicle group).
Reduced astrocyte activation (reduced GFAP+ cell count relative to vehicle group).
Downregulated pro-inflammatory mediators NF-κB and COX-2 in striatal and nigral tissues relative to vehicle group.
Reduced blood vessel leakage and BBB permeability relative to vehicle-treated 6-OHDA rats.
Increased expression of tight junction protein ZO-1 relative to vehicle group.
Increased NG2+ pericyte area density relative to vehicle group.
Increased survival of TH+ dopaminergic neurons in the striatum and substantia nigra relative to vehicle group.
Restored GABA transporter-positive neuron count in the striatum relative to vehicle group.
Restored CHAT+ neuron count in striatal and nigral tissues relative to vehicle group.
Reduced expression of neuronal apoptosis marker active caspase-3 relative to vehicle group.
Restored expression of synapse-associated protein Syn relative to vehicle group.
Reduced expression of PD progression marker pS129-α-syn relative to vehicle group.
Upregulated expression of neuronal activation marker cFos relative to vehicle group.
Suppressed upregulation of phospho-DARPP-32 relative to vehicle group.
Reversed downregulation of prodynorphin and upregulation of preproenkephalin relative to vehicle group.
分子量

1500.81

Formula

C73H113N17O17
CAS 号
Sequence

Lys-Ala-Phe-Asp-Ile-Thr-Tyr-Val-Arg-Leu-Lys-Phe
Sequence Shortening

KAFDITYVRLKF
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

KAFDITYVRLKF 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KAFDITYVRLKF208116-26-1IntegrinMMPMatrix metalloproteinasesParkinson's diseaseintegrin αvβ3neuronsB16-F10 mouse melanoma cellsendothelial cellsMMP-9melanomaLRRK2integrin α5β1monocytesInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
KAFDITYVRLKF
目录号：
HY-P11780
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z